Elicio Therapeutics Inc. (ELTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.94 (+4.02%), Market cap $0.19B, 52-week low–high $5.15 ~ $13.84.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headqua
Financial statements, price targets, institutional (13F) holdings and related news for Elicio Therapeutics Inc. are updated in real time on BlackAll Trade.
Elicio Therapeutics Inc. trades at $1.94 (+4.02%). Real-time quotes and charts are available on BlackAll Trade.
Elicio Therapeutics Inc. has a market cap of about $0.19B.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphi